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PANDEMIC POLITICS, PUBLIC HEALTH, AND 
THE FDA 
 
JORDAN PARADISE* & BECKY BAVLSIK 
 
“It is critical that the American public has complete confidence in this 
decision-making process. I want to assure them, and you, that the FDA will 
not authorize or approve any COVID-19 vaccine before it has met the 
Agency’s rigorous expectations for safety and effectiveness. In this effort, 
science will guide our decisions. FDA will not permit any pressure, from 
anybody, to change that. We can emerge from this pandemic only if we 
work together, learn from each other, and are driven by the facts and 
data.”1 FDA Commissioner Stephen Hahn, M.D., October 6, 2020.  
 
“New FDA rules make it more difficult for them to speed up vaccines for 
approval before Election Day. Just another political hit job!”2 President 
Donald J. Trump, October 6, 2020. 
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INTRODUCTION 
The U.S. Food and Drug Administration (FDA) is on the front lines 
of the COVID-19 pandemic. The agency is responsible for oversight of the 
vast spectrum of medical products necessary to protect health care workers 
and the general public, as well as fostering the rapid development and 
approval of life-saving detection methods and therapeutic products. The 
FDA is a long-embattled agency, tasked by Congress with the dual roles of 
both protecting the public health and facilitating innovation through rapid 
assessment of medical products. Recent legislation, such as the 21st Century 
Cures Act, intensifies these aspects of the FDA’s innovation mission by 
mandating the agency consider patient experience data, real-world 
evidence, and the increased use of biomarkers to demonstrate safety and 
efficacy, among other things. The FDA has been incrementally accelerating 
long-standing regulatory processes and expanding the sources of 
information consulted in product assessment in response to advisory 
committees, congressional directives, industry perspectives, and 
stakeholder input.3 
The FDA has historically operated independently and apolitically 
as a scientific agency guided by its public health mission.4 
Organizationally, the FDA is an executive branch agency housed within the 
broader Department of Health and Human Services (HHS), formerly led by 
Secretary Alex Azar from January 2018 to January 2021. Former FDA 
Commissioner Hahn, a radiation oncologist appointed by President Trump 
and who began in his official capacity in December 2019, had a tumultuous 
tenure as Commissioner given the coronavirus pandemic.5 Following 
 
3. See Jordan Paradise, Three Framings of “Faster” at the FDA and the 
Federal Right to Try, 11 WAKE FOREST J. L. & POL’Y 53 (2020). 
4. There have been notable instances of politically motivated agency and 
executive branch clashes, such as that of Plan B levonorgestrel-based emergency 
contraceptives. See Susan F. Wood, Inappropriate Obstructions to Access: The 
FDA’s Handling of Plan B, 16 AMA J. ETHICS 295 (2014). 
5. In late 2019, a novel coronavirus was discovered that was ultimately 
named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This virus 
causes the coronavirus disease, COVID-19. See Naming the Coronavirus Disease 
(COVID-19) and the Virus That Causes It, WORLD HEALTH ORG., 
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Secretary Azar’s January 31, 2020 declaration of a public health 
emergency, triggering FDA’s emergency authorities, the agency has been 
thrust into overdrive to carry out its responsibilities. In recent months, 
Secretary Azar and President Trump were pitted against Commissioner 
Hahn in various high-profile scenarios. Commissioner Hahn struggled 
against the President and HHS secretary for control over the timing and 
rigor of review and approval of vaccines and treatments for COVID-19. 
Commissioner Hahn has repeatedly assured the American public that the 
FDA will not cut corners on assessing the scientific data or jeopardize the 
public health and trust in the agency.6 Alternatively, President Trump has 
regularly commented on the “deep state” at the FDA and criticized the 
Commissioner for slowing down the approval process. Likewise, the media 
reported that “Angry Azar” had sights set on ousting Commissioner Hahn.7 
The pandemic politics are charged in an alarmingly unprecedented way 
among the White House, the HHS, and the FDA.  
Despite criticisms of his slowing down the regulatory process and 
defying the White House,8 Commissioner Hahn has openly commented on 
the need for the FDA to have more agility and flexibility in applying 
standards of product review in the face of the pandemic.9 Urging that the 
agency continue a sharp focus on the science and data, Commissioner Hahn 
had an interest in the discovery of new ways to structure clinical trial 
endpoints and expedite approval processes while maintaining statistical 




it (last visited Feb. 4, 2021). The COVID-19 outbreak was formally declared a 
pandemic on March 11, 2020. See WHO Director-General’s Opening Remarks at 
the Media Briefing on COVID-19 (Mar. 11, 2020), https://www.who.int/director-
general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-
briefing-on-covid-19---11-march-2020.  
6. Michael Mezher, Hahn Says COVID-19 Vaccines Will Be Reviewed in 
‘Real Time’, RAPS (July 28, 2020), https://www.raps.org/news-and-articles/news-
articles/2020/7/hahn-says-covid-19-vaccines-will-be-reviewed-in-re 
[https://perma.cc/M56X-JL8C] [hereinafter Mezher, COVID-19 Vaccines].  
7. Adam Cancryn & Dan Diamond, Angry Azar Floats Plans to Oust FDA’s 
Hahn, POLITICO (Oct. 22, 2020), https://www.politico.com/news/2020/10/22/azar-
plans-oust-hahn-fda-431139 [https://perma.cc/M7G4-GJ5D]. 
8. Id. 
9. Press Release, Coronavirus (COVID-19) Update: FDA Takes New 
Actions to Accelerate Development of Novel Prevention, Treatment Options for 




10. See Jaimy Lee, Five Things You Should Know About Stephen Hahn, the 
New FDA Commissioner, MARKET WATCH (Dec. 13, 2019), https://www.market
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COVID-19 by adapting and expanding existing policy include (1) support 
of decentralized clinical trials and increased use of telemedicine technology 
in clinical trials, (2) allowances for use of laboratory-developed tests in 
disease detection, (3) use of real-world evidence in drug and vaccine 
development, and (4) enhanced procedures for rapid assessment of 
expanded use requests for investigational drugs.11 The means by which the 
agency has achieved these policy adaptations is significant from an 
administrative law perspective; actions necessarily need to happen quickly 
and on the basis of accumulating information about the novel coronavirus.  
This article will explore the mechanisms by which the FDA 
achieved its policy adjustments in these four important areas and trace the 
history of the agency’s statutory and regulatory authority to do so. The 
article will also examine the scope of Trump Administration Executive 
Orders impacting administrative agency rulemaking and policy 
implementation,12 HHS directives regarding rulemaking procedures,13 and 
COVID-specific FDA guidance documents. The article will proceed in four 
parts. Part I introduces the statutory and regulatory basis of the FDA’s 
longstanding authority to issue policy through guidance documents directed 
to industry and agency personnel. This part is brief, yet foundational, and is 
included to frame later parts assessing recent FDA and executive branch 
activity. Part II explains the FDA’s traditional authority in product review 
and approval, as well as the agency’s role in pandemic preparedness and 
response. Part III analyzes FDA-issued guidance documents from January 
1, 2020, to October 6, 2020, keying in on topics and the impact of these 
guidance documents in order to survey the innovative nature of the 
guidance documents and their breadth and depth during the pandemic. A 
guidance published October 6, 2020, by the FDA entitled Emergency Use 
Authorizations for Vaccines to Prevent COVID-19 is illustrative of the rapid 
policymaking undertaken by the FDA to provide direction to industry about 
how products will be assessed and the measures employed to assure safety 
and efficacy as informed by statutory requirements. The guidance document 
is also the source of a contentious standoff between the White House and 
the agency that played out in October 2020. Part IV explores actions by the 
current White House and executive branch officials to impact the manner in 
which agencies develop and disseminate guidance documents, beginning 
 
watch.com/story/five-things-you-should-know-about-stephen-hahn-trumps-
nominee-to-head-fda-2019-11-21 [https://perma.cc/5GXN-6J9B] (discussing 
Commissioner Hahn’s Senate committee nomination hearing). 
11. Mezher, COVID-19 Vaccines, supra note 6. 
12. Exec. Order No. 13,924, 85 Fed. Reg. 31,353 (May 19, 2020); Exec. 
Order No. 13,891, 85 Fed. Reg. 55,235 (Oct. 19, 2019). 
13. Statement on Regulatory Process, U.S. DEPT. HEALTH & HUM. SERVS. 
(Sept. 20, 2020), https://www.hhs.gov/about/news/2020/09/20/hhs-statement-on-
regulatory-process.html [https://perma.cc/6X9M-QU2G]. 
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with an October 9, 2019 Executive Order and ending with an October 21, 
2020 Executive Order. These two Executive Orders serve as veritable 
bookends to the current administrative law tensions during the pandemic. 
Part V concludes. 
I.   CONGRESSIONAL AUTHORITY AND AGENCY POLICY ON GUIDANCE 
DOCUMENTS 
The FDA has long operated to communicate to industry utilizing 
guidance documents, which are policy interpretations that are not legally 
binding like congressionally enacted legislation or regulations promulgated 
through notice and comment rulemaking. Guidance documents are issued 
through less formal means by publication with notice in the Federal 
Register and publicly accessible document files on the agency website. The 
term guidance “refers to any written communication that explains an 
Agency or Center policy or procedure” and “generally refers to guidance 
for regulated entities (e.g., the pharmaceutical industry).”14 Guidance 
documents include, though are not limited to, “documents that relate to: 
[t]he design, production, labeling, promotion, manufacturing, and testing of 
regulated products; the processing, content, and evaluation or approval of 
submissions; and inspection and enforcement policies.”15 In 1997, the FDA 
expressly provided that guidance documents are nonbinding on the 
agency.16 This position was codified by Congress that same year and 
required FDA to develop good guidance practices, which the FDA 
subsequently did through notice and comment rulemaking.17 Among other 
things contained in the good guidance practices, the guidance document 
must state that the guidance “does not legally bind the public or FDA.”18  
Thus, the FDA has express congressional authority to issue 
guidance documents. The legislative language provides several key features 
for guidance documents issued by the agency through delegation of 
authority from the Secretary of HHS: 
(1)(A) The Secretary shall develop guidance documents 
with public participation and ensure that information 
identifying the existence of such documents and the 
documents themselves are made available to the public 
both in written form and, as feasible, through electronic 
 
14. Manual of Policies and Procedures 4000.2, U.S. FOOD & DRUG ADMIN. 
(2005), https://www.fda.gov/media/71702/download [https://perma.cc/KSB8-6DJ
J]. 
15. Food and Drugs, 21 C.F.R. § 10.115(b)(2) (2019). 
16. The Food and Drug Administration’s Development, Issuance, and Use of 
Guidance Documents, 62 Fed. Reg. 8,961 (1997). 
17. 21 C.F.R § 10.115. 
18. Id. 
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means. Such documents shall not create or confer any 
rights for or on any person, although they present the views 
of the Secretary on matters under the jurisdiction of the 
Food and Drug Administration. 
(B) Although guidance documents shall not be binding on 
the Secretary, the Secretary shall ensure that employees of 
the Food and Drug Administration do not deviate from 
such guidances without appropriate justification and 
supervisory concurrence. The Secretary shall provide 
training to employees in how to develop and use guidance 
documents and shall monitor the development and issuance 
of such documents. 
(C)(i) For guidance documents that set forth initial 
interpretations of a statute or regulation, changes in 
interpretation or policy that are of more than a minor 
nature, complex scientific issues, or highly controversial 
issues, the Secretary shall ensure public participation prior 
to implementation of guidance documents, unless the 
Secretary determines that such prior public participation is 
not feasible or appropriate. In such cases, the Secretary 
shall provide for public comment upon implementation and 
take such comment into account.19 
As a general matter, the FDA typically facilitates public 
participation through public meetings and notices in the Federal Register 
calling for stakeholder input on the development of guidance documents 
where appropriate, such as with matters that are “changes in interpretation 
or policy that are more than minor in nature” or relating to “highly 
controversial issues” or “complex scientific issues.”20 Guidance documents 
that fall into this category are designated by the FDA as “Level 1” guidance 
documents;21 those involving the explanation of existing practices or minor 
changes are designated “Level 2” guidance documents.22 The procedures 
for issuance of guidance documents are set forth in the regulations23 and 
each Center within the FDA has documented practices for the approval and 
issuance of guidance documents.24 Notices of draft and finalized guidance 
document are published in the Federal Register, and the FDA publishes the 
 
19. 21 U.S.C. § 371(h). 
20. Id. § 371(h)(C)(i). 
21. 21 C.F.R § 10.115(c)(1). 
22. Id. § 10.115(c)(2). 
23. Id. § 10.115(g). 
24. Id. § 10.115(j). 
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documents to the agency website.25 Guidance documents may be revised by 
the agency in response to industry and stakeholder input, or as the result of 
changing information and developments.26 Despite both the statute and 
FDA regulations noting that guidance documents are not legally binding, 
regulated industry routinely adheres to them as if they impart legal 
requirements, because courts oftentimes defer to the agency’s expertise as a 
function of inquiries into whether the FDA acted reasonably in light of 
scientific and technical matters. 
II.   THE FDA AND ITS ROLE IN PANDEMIC PREPAREDNESS AND 
RESPONSE 
The FDA is a specialized agency within the HHS, tasked with 
oversight of one quarter of consumer products, including food, cosmetics, 
drugs, biologics, medical devices, tobacco products, and products that emit 
radiation.27 Two federal statutes—the Food Drug and Cosmetic Act 
(FDCA)28 and the Public Health Safety Act (PHSA)29—set forth legal 
requirements across this range of products. Drugs, biologics, and medical 
devices are subject to the most rigorous requirements for development and 
manufacturing, clinical trials, product review, and clearance and approval. 
The highest risk products (new drugs, biologics, and life-saving and life-
sustaining medical devices) require well-controlled clinical trials 
demonstrating substantial evidence of safety and efficacy prior to market 
approval.30  
Each of these three product areas also have abbreviated routes to 
market based on comparativeness to other products already on the market.31 
Generic drugs are a useful example: where an applicant demonstrates 
bioequivalence to an innovator new drug product on the market, the 
threshold approval requirements are focused on the comparative aspects of 
those products, manufacturing processes, and labeling. There are also 
various expedited routes to market that speed innovations for promising 
products that address an unmet medical need, including breakthrough 
 
25. Id. § 10.115(n). 
26. Id. § 10.115(k). 
27. U.S. FOOD & DRUG ADMIN., GLOBAL ENGAGEMENT 2, 4, 10 (2013), 
https://www.ipqpubs.com/wp-content/uploads/2013/05/FDA_Global-
Engagement.pdf [https://perma.cc/87AN-JFN5].  
28. 21 U.S.C. § 301 et seq. 
29. 42 U.S.C. § 262. 
30. 21 U.S.C. § 355(b)(1) (new drugs); 21 U.S.C. §§ 360d, 360e (premarket 
approval medical devices); 42 U.S.C. § 262(j) (biologics). 
31. 21 U.S.C. § 355(j) (generic drugs); 21 U.S.C. §§ 360, 360c (“510(k)” 
medical devices); 42 U.S.C. § 262(k) (biosimilar and interchangeable biologics).  
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therapy status, Fast Track, and priority review.32 Expanded access 
mechanisms for investigational drugs and devices may also be utilized by 
the FDA for use in emergency situations.33 
Where there arises an emerging infectious disease; natural disaster; 
or chemical, biological, radiological, or nuclear (CBRN) emergency that 
threatens health and safety, the FDA has a substantial role in rapid 
response, including advancing measures to incentivize and support 
development of products, securing the product supply, and ensuring that 
safe and appropriate medical countermeasures (MCMs) are available.34 
Several foundational laws were enacted by Congress following the terrorist 
attacks of September 11, 2001, to establish mechanisms for coordination 
across federal agencies: the Public Health Security and Bioterrorism 
Preparedness and Response Act (Bioterrorism Act) of 2002,35 the Project 
BioShield Act of 2004,36 the Pandemic Readiness and Emergency 
Preparedness (PREP) Act of 2006,37 the Pandemic and All-Hazards 
Preparations Act (PAHPA) of 2006,38 and the Pandemic and All-Hazards 
Preparedness Reauthorization Act (PAHPRA) of 2013.39 The FDA’s 
emergency authorities are triggered when one of the Secretaries of Defense, 
Health and Human Services, or Homeland Security make a determination 
of emergency or significant potential for emergency or identification of a 
material threat.  
One of the most significant of the FDA’s emergency authorities is 
the emergency use authorization (EUA) procedure, first introduced in the 
Project Bioshield Act of 2004, and subsequently amended through 
legislation.40 In coordination with the HHS, the FDA may issue an EUA for 
an unapproved medical product where there is a serious or life-threatening 
illness or condition caused by CBRN agent as set forth in HHS declaration; 
 
32. Jordan Paradise, Three Framings of “Faster” at the FDA and the Federal 
Right to Try, 11 WAKE FOREST J. L. & POL’Y 74 (2020). 
33. Id. 
34. These consist of drugs, biologics, medical devices, and respiratory 
protective devices. U.S. FOOD & DRUG ADMIN., EMERGENCY USE AUTHORIZATION 
OF MEDICAL PRODUCTS & RELATED AUTHORITIES: GUIDANCE FOR INDUSTRY & 
OTHER STAKEHOLDERS 2 (2017) [hereinafter EUA MEDICAL PRODUCTS 
GUIDANCE]. 
35. Public Health Security and Bioterrorism Preparedness and Response Act 
of 2002, Pub. L. No. 107-188, 116 Stat. 594. 
36. Project BioShield Act of 2004, Pub. L. No. 108-276, 118 Stat. 835. 
37. Public Readiness and Emergency Preparedness Act, Pub. L. No. 109-148, 
119 Stat. 2818 (2006). 
38. Pandemic and All-Hazards Preparedness Act, Pub. L. No. 109-417, 120 
Stat. 2831 (2006). 
39. Pandemic and All-Hazards Preparedness Reauthorization Act of 2013, 
Pub. L. No. 113-5, 127 Stat. 161. 
40. Project BioShield Act of 2004, Pub. L. No. 108-276, 118 Stat. 835 (2004); 
21 U.S.C. § 360bbb-3. 
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reasonable belief that the product may be effective in diagnosing, treating, 
or preventing the illness or condition caused by the agent (based on totality 
of scientific data); the product’s known and potential benefits outweigh 
known and potential risks when used for disease or condition; and there is 
no adequate approved, available alternative.41 Where the FDA has already 
approved or cleared a medical product for a specific intended use, section 
564A of the FDCA grants the FDA the authority to allow for emergency 
use for a different intended use without EUA declaration and issuance.42 
The legislation extends beyond mere EUA issuance. Section 564A 
also provides for expiration date extensions, where safe and appropriate, to 
allow longer use of approved medicines and products. This also requires the 
development of emergency use instructions (EUIs) through coordination 
between HHS, FDA, and the Centers for Disease Control and Prevention 
(CDC). It also gives authority for emergency dispensing in the absence of a 
prescription and provides waivers for deviation from manufacturing 
standards and FDA-imposed risk evaluation and mitigation strategies.43 
Recipients of an EUA must develop detailed information about the product 
for health care professionals, authorized dispensers, and patients; must 
actively monitor and report adverse events; maintain records; and comply 
with all FDA-imposed requirements and limitations.44 Under section 
564(g)(2), an EUA may be revised or revoked if “the criteria for issuance 
are no longer met or other circumstances make such revocation appropriate 
to protect the public health or safety.”45  
Following the declaration of emergency from HHS Secretary Azar, 
the FDA has issued over one hundred medical device EUAs46 and several 
for drugs, including one for use of Remdesivir47 and one for the use of 
 
41. 21 U.S.C. § 360bbb-3(c); see also EUA MEDICAL PRODUCTS GUIDANCE, 
supra note 34, at 7–8. 
42. 21 U.S.C. § 360bbb-3(a). 
43. 21 U.S.C. § 360bbb-3(e); see also EUA MEDICAL PRODUCTS GUIDANCE, 
supra note 34, at 7–8. 
44. EUA MEDICAL PRODUCTS GUIDANCE, supra note 34, at 22–27. 
45. 21 U.S.C. § 360bbb-3(g)(2). 
46. U.S. FOOD & DRUG ADMIN., CORONAVIRUS DISEASE 2019 (COVID-19) 
EMERGENCY USE AUTHORIZATIONS FOR MEDICAL DEVICES (2020), 
https://www.fda.gov/medical-devices/emergency-use-authorizations-medical-
devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-
medical-devices [https://perma.cc/T2ED-5YYJ]. These EUAs span blood 
purification devices, renal replacement therapy devices, in vitro diagnostics, 
decontamination systems for personal protective equipment (PPE), infusion pumps, 
PPE, remote and wearable patient monitoring devices, respiratory assist devices, 
and ventilators and accessories. Id.  
47. Fact Sheet for Patients and Caregivers: Emergency Use Authorization of 
Veklury, GILEAD (Oct. 2020), https://www.gilead.com/-/media/files/pdfs/remdesivi
r%20/eua-fact-sheet-for-patients-and-caregivers.pdf [https://perma.cc/926U-9KW
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hydroxychloroquine, which was later revoked.48 The agency is still 
involved in clinic trial assessment and expedited evaluation processes for 
treatments and vaccines, including the issuances of EUAs for the Pfizer-
BioNTech vaccine on December 11, 2020, and the Moderna vaccine on 
December 18, 2020.49 The FDA has also focused acutely on enforcement 
activities against fraudulent and dangerous products promoted for use in 
fighting COVID-19 through utilization of warning letters, enforcement 
actions, and adverse publicity.50 However, much of the FDA’s work has 
been through guidance documents, as detailed in Part III. 
III.  SURVEYING FDA COVID-19 GUIDANCE DOCUMENTS 
In the wake of the COVID-19 pandemic, the FDA has acted 
through guidance documents to implement policy change across a broad 
range of topics. As a means to explore the breadth and depth of these 
guidance documents, we conducted a search of FDA-issued guidance 
documents and associated public notice of those documents in both the 
Federal Register and the FDA’s website. A search of the Federal Register 
for notices, rules, and proposed rules from the FDA from the time period of 
January 1, 2020, to October 8, 2020, that contained the search term “covid” 
 
2]; U.S. FOOD & DRUG ADMIN., FDA’S APPROVAL OF VEKLURY (REMDESIVIR) FOR 
THE TREATMENT OF COVID-19—THE SCIENCE OF SAFETY AND EFFECTIVENESS 
(2020); see also Jordan Paradise, COVID-IP: Staring Down the Bayh-Dole Act with 
2020 Vision, 7 J. L & BIOSCIENCES 10 (2020). 
48. U.S. Food & Drug Admin., Letter Revoking EUA for Chloroquine 
Phosphate and Hydroxychloroquine Sulfate, (June 15, 2020), https://www.fda.gov/
media/138945/download [https://perma.cc/YC24-6S5H].  
49. See Letter from Denise M. Hinton, Chief Scientist, Food & Drug Admin., 
to Elisa Harkins, Pfizer, Inc. (Dec. 23, 2020), https://www.fda.gov/media/144412/
download (informing Pfizer of the EUA grant for its vaccine); Letter from Denise 
M. Hinton, Chief Scientist, Food & Drug Admin., to Carlota Vinals, ModernaTX, 
Inc. (Dec. 18, 2020), https://www.fda.gov/media/144636/download (informing 
Moderna of the EUA grant for its vaccine); see also Press Release, Food & Drug 
Admin., FDA Takes Additional Action in Fight Against COVID-19 By Issuing 
Emergency Use Authorization for Second COVID-19 Vaccine (Dec. 18, 2020), 
https://www.fda.gov/news-events/press-announcements/fda-takes-additional-
action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid 
(“Through the FDA’s open and transparent scientific review process, two COVID-
19 vaccines have been authorized in an expedited timeframe while adhering to the 
rigorous standards for safety, effectiveness, and manufacturing quality needed to 
support emergency use authorization that the American people have come to expect 
from the FDA.” (quoting Comm’r Hahn)). 
50. Jordan Paradise & Elise Fester, FDA Publicity and Enforcement in the 
COVID Era, 60 WASHBURN L. REV. 77 (2020). 
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identified sixty-four results.51 The majority of the results from the Federal 
Register are merely notices of FDA activities, with only six rules52 and two 
proposed rules53 during the time frame. Of the remaining fifty-six results, 
thirty-three of the notices do not relate directly to the FDA’s response to the 
pandemic but rather appear in the search results because of a passing 
mention to the disease in relation to the decision to postpone a meeting or 
change to a virtual format.54 Of the twenty-three remaining results, twelve 
 
51. See FED. REG., federalregister.gov (search for “covid,” then select 
“advanced search,” then filter “Publication Date” for “01/01/2020 to 10/8/2020,” 
“Document Category” for “Rule” or “Proposed Rule” or “Notice,” and “Agency” 
for “Food and Drug Administration”). 
52. See Temporary Policy Regarding Accredited Third-Party Certification 
Program Onsite Observation and Certificate Duration Requirements During the 
COVID-19 Public Health Emergency: Guidance for Industry; Availability, 85 Fed. 
Reg. 23,919 (Apr. 30, 2020) (to be codified at 21 C.F.R. pt. 1); Temporary Policy 
Regarding Preventive Controls and FSVP Food Supplier Verification Onsite Audit 
Requirements During the COVID-19 Public Health Emergency: Guidance for 
Industry; Availability, 85 Fed. Reg. 17,008 (Mar. 26, 2020) (to be codified at 21 
C.F.R. pt. 1, 117, 507); Temporary Policy During the COVID-19 Public Health 
Emergency Regarding the Qualified Exemption from the Standards for the 
Growing, Harvesting, Packing, and Holding of Produce for Human Consumption: 
Guidance for Industry; Availability, 85 Fed. Reg. 34,508 (June 5, 2020) (to be 
codified at 21 C.F.R. pt. 112); Petition for an Administrative Stay of Action: 
Electrical Stimulation Devices for Self-Injurious or Aggressive Behavior, 85 Fed. 
Reg. 50,950 (Aug. 19, 2020) (to be codified at 21 C.F.R. pt. 882, 895); Tobacco 
Products; Required Warnings for Cigarette Packages and Advertisements; Delayed 
Effective Date, 85 Fed. Reg. 32,293 (May 29, 2020) (to be codified at 21 C.F.R. pt. 
1141); Regulatory Considerations for Human Cells, Tissues, and Cellular and 
Tissue-Based Products: Minimal Manipulation and Homologous Use: Guidance for 
Industry and Food and Drug Administration Staff; Availability, 85 Fed. Reg. 
43,989 (July 21, 2020) (to be codified at 21 C.F.R. pt. 1271). 
53. See Requirements for Additional Traceability Records for Certain Foods; 
Proposed Rule; Public Meetings; Request for Comments, 85 Fed. Reg. 62,632 
(proposed Oct. 5, 2020); Laboratory Accreditation for Analyses of Foods; 
Extension of Comment Period, 85 Fed. Reg. 19,114 (proposed Apr. 6, 2020). 
54. See, e.g., Joint Meeting of the Anesthetic and Analgesic Drug Products 
Advisory Committee and the Drug Safety and Risk Management Advisory 
Committee; Notice of Meeting; Establishment of a Public Docket; Request for 
Comments, 85 Fed. Reg. 63,284 (Oct. 7, 2020); Agency Information Collection 
Activities; Proposed Collection; Comment Request; Orphan Drugs, 85 Fed. Reg. 
62,306, 62,308 (Oct. 2, 2020) (appearing because of a single mention of COVID-
19 related to the decision to accept orphan drug-related submissions and documents 
via email); Patient-Focused Drug Development for Stimulant Use Disorder; Public 
Meeting; Request for Comments, 85 Fed. Reg. 61,756 (Sept. 30, 2020); 
Prescription Drug User Fee Rates for Fiscal Year 2021, 85 Fed. Reg. 46,651, 
46,654–55 (Aug. 3, 2020) (appearing in the search results because of two mentions 
that COVID-19 may affect the PDUFA workload); Pediatric Advisory Committee; 
Notice of Meeting; Establishment of a Public Docket; Request for Comments, 85 
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of them are notice of either the issuance or withdrawal of specific 
individual guidance documents,55 and three are notices of specific EUA 
revocations and authorizations.56 
 
Fed. Reg. 44,541 (July 23, 2020); Cardiovascular and Renal Drugs Advisory 
Committee; Notice of Meeting; Establishment of a Public Docket; Request for 
Comments, 85 Fed. Reg. 41,053 (July 8, 2020); Agency Information Collection 
Activities; Submission for Office of Management and Budget Review; Comment 
Request; Health Care Providers' Understanding of Opioid Analgesic Abuse 
Deterrent Formulations, 85 Fed. Reg. 40,663 (July 7, 2020); Oncologic Drugs 
Advisory Committee; Notice of Meeting; Establishment of a Public Docket; 
Request for Comments, 85 Fed. Reg. 37,458 (June 22, 2020); Submission of Plans 
for Cigarette Packages and Cigarette Advertisements (Revised); Guidance for 
Industry; Availability, 85 Fed. Reg. 32,401, 32,402 (May 29, 2020) (mentioning 
COVID-19 only one time in reference to a postponement of an effective date); 
Ophthalmic Devices Panel of the Medical Devices Advisory Committee: Notice of 
Meeting; Postponement, 85 Fed. Reg. 23,970 (Apr. 30, 2020); Fiscal Year 2020 
Generic Drug Regulatory Science Initiatives; Public Workshop; Remote Only, 85 
Fed. Reg. 23,968 (Apr. 30, 2020); Pulmonary-Allergy Drugs Advisory Committee; 
Postponed, 85 Fed. Reg. 19,491 (Apr. 7, 2020); Blood Products Advisory 
Committee; Postponed, 85 Fed. Reg. 16,368 (Mar. 23, 2020). 
55. See Investigational COVID-19 Convalescent Plasma; Guidance for 
Industry; Withdrawal of Guidance; Correction, 85 Fed. Reg. 63,277 (Oct. 7, 2020); 
Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent 
Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 
Prevention or Treatment; Guidance for Industry; Availability, 85 Fed. Reg. 61,008 
(Sept. 29, 2020); Investigational COVID-19 Convalescent Plasma; Guidance for 
Industry; Availability, 85 Fed. Reg. 59,319 (Sept. 21, 2020) (superseding the 
earlier guidance document by the same name); Investigational COVID-19 
Convalescent Plasma; Guidance for Industry; Withdrawal of Guidance, 85 Fed. 
Reg. 59,320 (Sept. 21, 2020); Revised Recommendations for Reducing the Risk of 
Human Immunodeficiency Virus Transmission by Blood and Blood Products; 
Guidance for Industry; Availability, 85 Fed. Reg. 36,595 (June 17, 2020); Revised 
Recommendations To Reduce the Risk of Transfusion-Transmitted Malaria; 
Guidance for Industry; Availability, 85 Fed. Reg. 36,598 (June 17, 2020). 
Institutional Review Board Review of Individual Patient Expanded Access 
Requests for Investigational Drugs and Biological Products During the COVID-19 
Public Health Emergency; Guidance for Institutional Review Boards and Clinical 
Investigators; Availability, 85 Fed. Reg. 35,311 (June 9, 2020); COVID-19: 
Developing Drugs and Biological Products for Treatment or Prevention; Guidance 
for Industry; Availability, 85 Fed. Reg. 29,949 (May 19, 2020); Policy for 
Coronavirus Disease-2019 Tests During the Public Health Emergency; 
Immediately in Effect Guidance for Clinical Laboratories, Commercial 
Manufacturers, and Food and Drug Administration Staff; Availability, 85 Fed. Reg. 
29,461 (May 15, 2020); Notifying the Food and Drug Administration of a 
Permanent Discontinuance or Interruption in Manufacturing Under Section 506C 
of the Federal Food, Drug, and Cosmetic Act; Guidance for Industry; Availability, 
85 Fed. Reg. 18,247 (Apr. 1, 2020); Policy for Temporary Compounding of Certain 
Alcohol-Based Hand Sanitizer Products During the Public Health Emergency; 
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The remaining results include two notices establishing a new 
process for bulk publishing of guidance documents57 and EUAs58 rather 
than publishing each one individually as is the regular procedure for 
publication of notice to the public. These two bulk-publishing process 
notices detail the FDA’s modified guidance and EUA notice procedure in 
light of the pandemic.59 Citing efficiency concerns, the FDA announced 
that it would publish guidance documents and EUAs without prior notice 
and comment, but it would still solicit and review comments and then 
revise the guidance documents as necessary.60 Thus, rather than issuance of 
 
Immediately in Effect Guidance for Industry; Availability, 85 Fed. Reg. 16,370 
(Mar. 23, 2020); Policy for Diagnostics Testing in Laboratories Certified to 
Perform High Complexity Testing Under the Clinical Laboratory Improvement 
Amendments Prior to Emergency Use Authorization for Coronavirus Disease-2019 
During the Public Health Emergency; Immediately in Effect Guidance for Clinical 
Laboratories and Food and Drug Administration Staff; Availability, 85 Fed. Reg. 
13,169 (Mar. 6, 2020). 
56. See Revocation of Authorizations of Emergency Use of In Vitro 
Diagnostic Devices for Detection of Antibodies Against SARS-CoV-2, 85 Fed. 
Reg. 62,739 (Oct. 5, 2020) (reprinting the FDA’s rationale for revoking Autobio’s 
EUA for a diagnostic test); Authorizations and Revocation of Emergency Use of 
Drugs During the COVID-19 Pandemic; Availability, 85 Fed. Reg. 56,231 (Sept. 
11, 2020) (reprinting the conditions for the new drug EUAs and rationale for 
revoking BARDA’s drug EUA); Revocation of Authorization of Emergency Use of 
an In Vitro Diagnostic Device for Detection of Antibodies Against SARS-CoV-2, 
85 Fed. Reg. 42,414 (July 14, 2020) (reprinting the explanation for the revocation 
of Chembio’s diagnostic medical device EUA). 
57. See Process for Making Available Guidance Documents Related to 
Coronavirus Disease 2019, 85 Fed. Reg. 16,949 (Mar. 25, 2020). 
58. See Process for Publishing Emergency Use Authorizations for Medical 
Devices During Coronavirus Disease 2019, 85 Fed. Reg. 33,685 (June 2, 2020). 
59. See Process for Making Available Guidance Documents Related to 
Coronavirus Disease 2019, 85 Fed. Reg. at 16,949 (announcing the FDA’s intent to 
periodically publish a consolidated Notice of Availability in the Federal Register 
rather than a separate Notice of Availability for each COVID-19-related guidance 
document); Process for Publishing Emergency Use Authorizations for Medical 
Devices During Coronavirus Disease 2019, 85 Fed. Reg. at 33,685 (announcing the 
FDA’s intent to periodically publish a consolidated Notice of Availability 
containing all the COVID-19-related EUAs during the relevant period rather than 
an individual Notice of Availability for each EUA issued). 
60. Process for Making Available Guidance Documents Related to 
Coronavirus Disease 2019, 85 Fed. Reg. at 16,949 (“In light of the need to act 
quickly and efficiently to respond to the COVID-19 public health emergency, FDA 
anticipates that prior public participation will not be feasible or appropriate before 
FDA implements COVID-19-related guidance documents. FDA anticipates it will 
issue COVID-19-related guidance documents for immediate implementation 
without prior public comment . . . . Although FDA expects that COVID-19-related 
guidances will be implemented without prior comment, FDA will solicit comment, 
review all comments received, and revise the guidance documents as appropriate 
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an individual notice for every individual guidance and EUA issued, the 
search reveals six bulk notices for the guidance document summaries61 and 
two notices for the EUA summaries.62 These results are summarized in the 
Table 1 below.  
Table 1: Federal Register Search Results for FDA COVID-19 Activity 
(Janary 1, 2020 – October 8, 2020) 
Type of Activity Number of results 
Notices 56 
Notice of procedural change for 
publication of COVID actions 2 
Notice of compiled EAU 
authorization/revocations 2 
Notice of compiled guidance documents 6 
 
. . . . Rather than publishing a separate Notice of Availability (NOA) for each 
COVID-19-related guidance document, FDA intends to publish periodically a 
consolidated NOA. This periodic NOA will announce the availability of all the 
COVID-19-related guidance documents that issued during the relevant period. The 
consolidated NOA will provide instructions to the public on submitting comments 
on COVID-19-related guidance documents, including the docket number(s) 
associated with each guidance document, information on how to view the dockets, 
and instructions for persons interested in obtaining a copy of a COVID-19-related 
guidance document.”); Process for Publishing Emergency Use Authorizations for 
Medical Devices During Coronavirus Disease 2019, 85 Fed. Reg. 33,686 (“Rather 
than publishing a separate Notice of Availability (NOA) for each COVID-19 
related EUA for a medical device, FDA intends to publish periodically a 
consolidated NOA. This periodic NOA will announce the availability of all the 
COVID-19 related EUAs for medical devices that issued during the relevant 
period.”). 
61. See Guidance Documents Related to Coronavirus Disease 2019; 
Availability, 85 Fed. Reg. 55,678 (Sept. 9, 2020); Guidance Documents Related to 
Coronavirus Disease 2019; Availability, 85 Fed. Reg. 46,641 (Aug. 3, 2020); 
Guidance Documents Related to Coronavirus Disease 2019 (COVID-19); 
Availability, 85 Fed. Reg. 38,372 (June 26, 2020); Guidance Documents Related to 
Coronavirus Disease 2019 (COVID-19); Availability, 85 Fed. Reg. 31,513 (May 
26, 2020); Guidance Documents Related to Coronavirus Disease 2019 (COVID-
19); Availability, 85 Fed. Reg. 28,010 (May 12, 2020); Product-Specific 
Guidances; Guidance for Industry; Availability, 85 Fed. Reg. 20,694 (Apr. 14, 
2020). 
62. See Authorization of Emergency Use of Certain Medical Devices During 
COVID-19; Availability, 85 Fed. Reg. 42,407 (July 14, 2020); Authorization of 
Emergency Use of Certain Medical Devices During COVID-19; Availability, 85 
Fed. Reg. 34,638 (June 5, 2020).  
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Notice of individual guidance documents 12 
Notice of individual EAU 
authorizations/revocations 3 
Notices related to committee meetings and 
information collection 33 
Rules 6 
Guidance documents 4 
Petition for an Administrative Stay of 
Action 1 
Delayed effective date 1 
Proposed Rules 2 
TOTAL 64 
 
While the Federal Register search revealed only twelve specific 
guidance documents in response to the pandemic, the FDA has actually 
issued sixty-three COVID-19-related guidance documents as of October 8, 
2020.63 The FDA has compiled all of its COVID-related information on its 
website, easily accessible from the FDA.gov homepage.64 On its COVID 
resource page, it links to its compilation of all the COVID-19-related 
guidance documents, organized in a searchable table, categorized by title, 
type, product area, and date posted.65 Of those sixty-three guidance 
documents, sixty-one were final guidance documents and only two were 
 
63. See COVID-19-Related Guidance Documents for Industry, FDA Staff, and 
Other Stakeholders, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/emergency-
preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-related-
guidance-documents-industry-fda-staff-and-other-stakeholders 
[https://perma.cc/X3UJ-RAUU] (last updated Dec. 23, 2020). 
64. See Coronavirus Disease 2019 (COVID-19), U.S. FOOD & DRUG ADMIN., 
https://www.fda.gov/emergency-preparedness-and-response/counterterrorism-and-
emerging-threats/coronavirus-disease-2019-covid-19 [https://perma.cc/2EFU-R9G
C] (last visited Oct. 8, 2020) (compiling the FDA’s latest COVID-19 news, safety 
warnings, EUAs, personal protective equipment updates, frequently asked 
questions, and contact information); see also U.S. FOOD & DRUG ADMIN., 
https://www.fda.gov/ [https://perma.cc/Z39K-TJ2H] (last visited Aug. 12, 2020) 
(featuring in the top center of its homepage in large, bolded print a single clickable 
link to the FDA’s COVID-19 page reading “FDA Takes Action to Address 
Coronavirus Disease 2019 (COVID-19)” with smaller, text underneath “FDA is 
working with U.S. Government partners, including CDC, and international partners 
to address the pandemic.”). 
65. See COVID-19-Related Guidance Documents for Industry, FDA Staff, and 
Other Stakeholders, supra note 63 (accessible by clicking on the second list item 
on the left-hand menu of the FDA’s COVID-19 main resource page). 
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immediately in effect guidance documents.66 The following tables, Table 2 
and Table 3, show the breakdown of guidance documents by product area 
and guidance type, as categorized by the FDA.67 The categorizations often 
overlap, meaning that multiple product areas or multiple audiences are 
involved in a given guidance document. 
Table 2: Guidance Documents by Product Area  
Product Area Number of Guidance 
documents 
Medical Devices 23 
Drugs 24 
Biologics 22 
Food & Beverages 11 
Animal & Veterinary 8 
 
Table 3: Guidance Documents by Audience 
 
Guidance Audience Number of Guidance 
documents 
Industry 54 
FDA Staff 20 
Clinical Laboratories 3 
Investigators 3 
Commercial Manufacturers 2 
Institutional Review Boards (IRBs) 2 
Health Care Professionals 2 
Generic Drug Development  1 
 
66. The two immediately in effect guidances were U.S. FOOD & DRUG 
ADMIN., POLICY FOR TEMPORARY COMPOUNDING OF CERTAIN ALCOHOL-BASED 
HAND SANITIZER PRODUCTS DURING THE PUBLIC HEALTH EMERGENCY (Aug. 7, 
2020) and U.S. FOOD & DRUG ADMIN., POLICY FOR CORONAVIRUS DISEASE-2019 
TESTS DURING THE PUBLIC HEALTH EMERGENCY (REVISED) (May 11, 2020) 
[hereinafter COVID-19 TESTS GUIDANCE]. 
67. Several of the guidances have multiple product areas and audiences listed. 
This table counts each label for each guidance, resulting in double-counting of 
several guidances which is why the total would be higher than sixty-three.  
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Egg Producers 1 
 
The Appendix to this article identifies all of these guidance 
documents by title, type, product area, audience, and date. Of these sixty-
three guidance documents identified by the FDA on the website, they can 
further be categorized as “innovative” and “non-innovative” in substance 
and form. Many of the guidance documents simply eased reporting 
requirements temporarily;68 loosened enforcement guidelines on low-risk 
medical devices like disinfectants,69 masks,70 hospital gowns,71 and 
electronic thermometers;72 or modified enforcement for high-risk medical 
 
68. U.S. FOOD & DRUG ADMIN., NOTIFYING CDRH OF A PERMANENT 
DISCONTINUANCE OR INTERRUPTION IN MANUFACTURING OF A DEVICE UNDER 
SECTION 506J OF THE FD&C ACT DURING THE COVID-19 PUBLIC HEALTH 
EMERGENCY (June 19, 2020); U.S. FOOD & DRUG ADMIN., POSTMARKETING 
ADVERSE EVENT REPORTING FOR MEDICAL PRODUCTS AND DIETARY 
SUPPLEMENTS DURING A PANDEMIC (May 8, 2020); U.S. FOOD & DRUG ADMIN., 
REPORTING AND MITIGATING ANIMAL DRUG SHORTAGES DURING THE COVID-19 
PUBLIC HEALTH EMERGENCY (May 7, 2020); see also U.S. FOOD & DRUG ADMIN., 
POLICY FOR CERTAIN REMS REQUIREMENTS DURING THE COVID-19 PUBLIC 
HEALTH EMERGENCY GUIDANCE FOR INDUSTRY AND HEALTH CARE 
PROFESSIONALS (Mar. 22, 2020) (temporarily suspending enforcement of REMS 
that would require in-person imaging or laboratory testing if there is no compelling 
reason to complete the test). 
69. U.S. FOOD & DRUG ADMIN., TEMPORARY POLICY FOR MANUFACTURE OF 
ALCOHOL FOR INCORPORATION INTO ALCOHOL-BASED HAND SANITIZER PRODUCTS 
DURING THE PUBLIC HEALTH EMERGENCY (COVID-19) (June 1, 2020); U.S. FOOD 
& DRUG ADMIN., TEMPORARY POLICY FOR PREPARATION OF CERTAIN ALCOHOL-
BASED HAND SANITIZER PRODUCTS DURING THE PUBLIC HEALTH EMERGENCY 
(COVID-19) (June 1, 2020); U.S. FOOD & DRUG ADMIN., ENFORCEMENT POLICY 
FOR STERILIZERS, DISINFECTANT DEVICES, AND AIR PURIFIERS DURING THE 
CORONAVIRUS DISEASE 2019 (COVID-19) PUBLIC HEALTH EMERGENCY (Mar. 29, 
2020); U.S. FOOD & DRUG ADMIN., POLICY FOR TEMPORARY COMPOUNDING OF 
CERTAIN ALCOHOL-BASED HAND SANITIZER PRODUCTS DURING THE PUBLIC 
HEALTH EMERGENCY (Mar. 29, 2020) [hereinafter COMPOUNDING HAND 
SANITIZER GUIDANCE]. 
70. U.S. FOOD & DRUG ADMIN., ENFORCEMENT POLICY FOR FACE MASKS 
AND RESPIRATORS DURING THE CORONAVIRUS DISEASE (COVID-19) PUBLIC 
HEALTH EMERGENCY (REVISED) (May 2020). 
71. U.S. FOOD & DRUG ADMIN., ENFORCEMENT POLICY FOR GOWNS, OTHER 
APPAREL, AND GLOVES DURING THE CORONAVIRUS DISEASE (COVID-19) PUBLIC 
HEALTH EMERGENCY (Mar. 30, 2020). 
72. U.S. FOOD & DRUG ADMIN., ENFORCEMENT POLICY FOR CLINICAL 
ELECTRONIC THERMOMETERS DURING THE CORONAVIRUS DISEASE 2019 (COVID-
19) PUBLIC HEALTH EMERGENCY (Apr. 4, 2020). 
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devices directly related to treatment.73 A few guidance documents were 
aimed at addressing complications in transportation and the supply chain 
for food and drugs,74 while others temporarily amended food labeling 
policies.75 Several guidance documents focus directly on COVID-19 
 
73. U.S. FOOD & DRUG ADMIN., POLICY FOR THE TEMPORARY USE OF 
PORTABLE CRYOGENIC CONTAINERS NOT IN COMPLIANCE WITH 21 CFR 
211.94(E)(1) FOR OXYGEN AND NITROGEN DURING THE COVID-19 PUBLIC 
HEALTH EMERGENCY (Apr. 20, 2020); U.S. FOOD & DRUG ADMIN., ENFORCEMENT 
POLICY FOR EXTRACORPOREAL MEMBRANE OXYGENATION AND 
CARDIOPULMONARY BYPASS DEVICES DURING THE CORONAVIRUS DISEASE 2019 
(COVID-19) PUBLIC HEALTH EMERGENCY (Apr. 6, 2020); U.S. FOOD & DRUG 
ADMIN., ENFORCEMENT POLICY FOR INFUSION PUMPS AND ACCESSORIES DURING 
THE CORONAVIRUS DISEASE 2019 (COVID-19) PUBLIC HEALTH EMERGENCY (Apr. 
5, 2020); U.S. FOOD & DRUG ADMIN., ENFORCEMENT POLICY FOR VENTILATORS 
AND ACCESSORIES AND OTHER RESPIRATORY DEVICES DURING THE CORONAVIRUS 
DISEASE 2019 (COVID-19) PUBLIC HEALTH EMERGENCY (Mar. 22, 2020). 
74. U.S. FOOD & DRUG ADMIN., ENFORCEMENT POLICY FOR VIRAL 
TRANSPORT MEDIA DURING THE CORONAVIRUS DISEASE 2019 (COVID-19) PUBLIC 
HEALTH EMERGENCY (July 20, 2020); U.S. FOOD & DRUG ADMIN., TEMPORARY 
POLICY DURING THE COVID-19 PUBLIC HEALTH EMERGENCY REGARDING THE 
QUALIFIED EXEMPTION FROM THE STANDARDS FOR THE GROWING, HARVESTING, 
PACKING, AND HOLDING OF PRODUCE FOR HUMAN CONSUMPTION (May 22, 2020); 
U.S. FOOD & DRUG ADMIN., TEMPORARY POLICY FOR COMPOUNDING OF CERTAIN 
DRUGS FOR HOSPITALIZED PATIENTS BY OUTSOURCING FACILITIES DURING THE 
COVID-19 PUBLIC HEALTH EMERGENCY (REVISED) (May 21, 2020); U.S. FOOD & 
DRUG ADMIN., TEMPORARY POLICY FOR COMPOUNDING OF CERTAIN DRUGS FOR 
HOSPITALIZED PATIENTS BY PHARMACY COMPOUNDERS NOT REGISTERED AS 
OUTSOURCING FACILITIES DURING THE COVID-19 PUBLIC HEALTH EMERGENCY 
(REVISED) (May 21, 2020); U.S. FOOD & DRUG ADMIN., EXEMPTION AND 
EXCLUSION FROM CERTAIN REQUIREMENTS OF THE DRUG SUPPLY CHAIN SECURITY 
ACT DURING THE COVID-19 PUBLIC HEALTH EMERGENCY (Apr. 30, 2020); U.S. 
FOOD & DRUG ADMIN., TEMPORARY POLICY REGARDING ENFORCEMENT OF 21 
CFR PART 118 (THE EGG SAFETY RULE) DURING THE COVID-19 PUBLIC HEALTH 
EMERGENCY (Apr. 6, 2020) [hereinafter EGG SAFETY RULE GUIDANCE] (permitting 
vendors who normally would only sell eggs for further processing to sell to the 
table egg market if needed and certain conditions are met to address the market 
imbalance in demand for table eggs versus eggs from restaurants and other similar 
establishments). 
75. U.S. FOOD & DRUG ADMIN., TEMPORARY POLICY REGARDING PACKAGING 
AND LABELING OF SHELL EGGS SOLD BY RETAIL FOOD ESTABLISHMENTS DURING 
THE COVID-19 PUBLIC HEALTH EMERGENCY (Apr. 3, 2020); U.S. FOOD & DRUG 
ADMIN., TEMPORARY POLICY REGARDING NUTRITION LABELING OF STANDARD 
MENU ITEMS IN CHAIN RESTAURANTS AND SIMILAR RETAIL FOOD 
ESTABLISHMENTS DURING THE COVID-19 PUBLIC HEALTH EMERGENCY (Apr. 1, 
2020); U.S. FOOD & DRUG ADMIN., TEMPORARY POLICY REGARDING NUTRITION 
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diagnostic testing,76 treatment,77 and vaccine development.78 And some 
guidance documents were promulgated to fill gaps for issues the FDA had 
never encountered before, such as returning refrigerated transport vehicles 
to food use after using them to preserve human remains79 and adjusting 
statistical analyses to account for COVID-19 complications in clinical 
trials.80  
Many of the guidance documents promulgated by the FDA in 
response to COVID-19 simply addressed issues that had never arisen 
before. For example, in May 2020 the FDA had to issue a guidance 
detailing proper procedure for returning refrigerated transport vehicles to 
food uses after using them to preserve human remains.81 The guidance 
notes that the COVID-19 pandemic has necessitated additional refrigerated 
storage and recognized that vehicles usually used for food may be instead 
used to store human remains.82 The FDA stated that it had received 
questions about if and how these vehicles and storage units could be 
returned to their intended use, so they responded by issuing a guidance 
intended to supplement existing regulations on cleaning and disinfecting 
these vehicles.83 Similarly, the COVID-19 pandemic led to increased 
 
LABELING OF CERTAIN PACKAGED FOOD DURING THE COVID-19 PUBLIC HEALTH 
EMERGENCY (Mar. 26, 2020).  
76. COVID-19 TESTS GUIDANCE, supra note 66. 
77. U.S. FOOD & DRUG ADMIN., PRODUCT-SPECIFIC GUIDANCES FOR 
CHLOROQUINE PHOSPHATE AND HYDROXYCHLOROQUINE SULFATE (Apr. 13, 2020). 
78. See U.S. FOOD & DRUG ADMIN., DEVELOPMENT AND LICENSURE OF 
VACCINES TO PREVENT COVID-19 (June 30, 2020) [hereinafter DEVELOPMENT 
AND LICENSURE OF VACCINES GUIDANCE]. 
79. U.S. FOOD & DRUG ADMIN., RETURNING REFRIGERATED TRANSPORT 
VEHICLES AND REFRIGERATED STORAGE UNITS TO FOOD USES AFTER USING THEM 
TO PRESERVE HUMAN REMAINS DURING THE COVID-19 PANDEMIC (May 12, 
2020) [hereinafter REFRIGERATED STORAGE RETURN GUIDANCE]. 
80. U.S. FOOD & DRUG ADMIN., STATISTICAL CONSIDERATIONS FOR CLINICAL 
TRIALS DURING THE COVID-19 PUBLIC HEALTH EMERGENCY GUIDANCE FOR 
INDUSTRY (June 16, 2020). 
81. See REFRIGERATED STORAGE RETURN GUIDANCE, supra note 79; see also 
Rachel Premack, The FDA Just Released a Ghoulish Handbook for How to 
Convert Trucks from Storing Coronavirus Victims' Bodies to Hauling Food, BUS. 
INSIDER (May 13, 2020, 4:40 PM), https://www.businessinsider.com/coronavirus-
federal-memo-reveals-trucks-used-for-dead-2020-5 [https://perma.cc/7TAT-SYJY] 
(highlighting the role food cold storage vehicles have played in storing COVID-19 
victims’ remains); Jeremy Rose, As an ER Doctor, I Fear Our Era’s Defining 
Symbol Will Be the Refrigerator Truck, WASH. POST (Apr. 11, 2020, 5:05 PM), 
https://www.washingtonpost.com/outlook/2020/04/11/refrigerated-truck-morgue-
coronavirus/ [https://perma.cc/9E8F-89GZ]. 
82. REFRIGERATED STORAGE RETURN GUIDANCE, supra note 79. 
83. REFRIGERATED STORAGE RETURN GUIDANCE, supra note 79, at 4. 
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demand for essential sanitizers and disinfectants.84 In order to alleviate the 
demand while still promoting effective sanitizers, the FDA eased 
enforcement to allow state-licensed pharmacies, federal facilities, and 
registered outsourcing facilities to make their own sanitizers, provided they 
follow the FDA’s recipe precisely.85 Likewise, as a prophylactic measure 
against an anticipated egg shortage86 due to COVID-19 supply chain 
disruptions, the FDA implemented a temporary policy permitting egg 
producers who currently only sell eggs to facilities for further processing to 
sell directly to consumers in retail establishments.87 All of the 
aforementioned guidance documents arose out of the novel circumstances 
created by the COVID-19 pandemic, but the policies enacted are not likely 
to continue beyond the emergency. 
However, other guidance documents significantly expanded FDA 
policy in certain areas, including telemedicine,88 clinical trials,89 and remote 
 
84. See, e.g., Chloe Taylor, Sales of Hand Sanitizer Are Skyrocketing Due to 
the Coronavirus, Leading to Rationing and Price Hikes, CNBC (Mar. 3, 2020, 9:22 
AM), https://www.cnbc.com/2020/03/03/coronavirus-hand-sanitizer-sales-surge-
leading-to-price-hikes.html [https://perma.cc/Z8VD-QRVC] (citing a 255% year-
on-year increase in hand sanitizer sales in February 2020); Ganda Suthivarakom, 
Coronavirus Has Caused a Hand Sanitizer Shortage. What Should You Do?, N.Y. 
TIMES (Mar 11, 2020), https://www.nytimes.com/2020/03/11/smarter-living/wire
cutter/coronavirus-hand-sanitizer.html [https://perma.cc/K622-8YGZ] 
(documenting the shortage of hand sanitizers and providing do-it-yourself recipes 
and other recommendations for alternative sanitizing methods). 
85. See COMPOUNDING HAND SANITIZER GUIDANCE, supra note 69; see also 
Jacquie Lee, Hand Sanitizer Shortages Push FDA to Let Pharmacists Make It, 
BLOOMBERG (Mar. 14, 2020, 12:54 PM), https://www.bloomberg.com/news/
articles/2020-03-14/hand-sanitizer-shortages-push-fda-to-let-pharmacists-make-it 
[https://perma.cc/G5K7-WVWC].  
86. See Lauren Reiley, Stress-Baking and Hoarding Have Led to a Retail Egg 
Shortage. There Are Eggs in the Pipeline, but Maybe Not Enough, WASH. POST 
(Mar. 26, 2020, 6:33 PM), https://www.washingtonpost.com/business/2020/03/26/
shortages-eggs-stress-baking/ [https://perma.cc/HK4Y-4AG6]. 
87. See EGG SAFETY RULE GUIDANCE, supra note 74. 
88. See U.S. FOOD & DRUG ADMIN., ENFORCEMENT POLICY FOR REMOTE 
DIGITAL PATHOLOGY DEVICES DURING THE CORONAVIRUS DISEASE 2019 (COVID-
19) PUBLIC HEALTH EMERGENCY (Apr. 24, 2020) [hereinafter REMOTE DIGITAL 
PATHOLOGY GUIDANCE]; U.S. FOOD & DRUG ADMIN., ENFORCEMENT POLICY FOR 
DIGITAL HEALTH DEVICES FOR TREATING PSYCHIATRIC DISORDERS DURING THE 
CORONAVIRUS DISEASE 2019 (COVID-19) PUBLIC HEALTH EMERGENCY (Apr. 14, 
2020). 
89. See U.S. FOOD & DRUG ADMIN., FDA GUIDANCE ON CONDUCT OF 
CLINICAL TRIALS OF MEDICAL PRODUCTS DURING COVID-19 PUBLIC HEALTH 
EMERGENCY (updated Dec. 4, 2020) [hereinafter CLINICAL TRIALS OF MEDICAL 
PRODUCTS GUIDANCE]. 
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monitoring devices.90 These guidance documents appear to have the 
potential to have impacts beyond the pandemic and indicate a shift in FDA 
action. These far-reaching guidance documents can be categorized as 
“innovative,” as opposed to the non-innovative guidance documents 
temporarily in effect to manage immediate extenuating circumstances. For 
example, the Guidance on Conduct of Clinical Trials of Medical Products 
During COVID-19 originally published on March 18, 2020, allowed for 
modifications to protocols without prior Institutional Review Board (IRB) 
approval.91 Additionally, it permitted remote monitoring so that participants 
would not have to submit to in-person testing.92 Furthermore, it allowed for 
medications to be sent directly to participants in certain studies, where 
appropriate.93 The FDA also issued several guidance documents that 
permitted remote monitoring of patients94 as well as remote ophthalmic 
assessments,95 remote maternal and fetal monitoring,96 and remote digital 
pathology devices.97 Likewise, the FDA expanded the authority for 
investigators to modify clinical trial protocols without preclearance from 
the IRB or notification to the FDA.98 As part of these protocol 
modifications, the FDA allowed investigators to shift to remote monitoring, 
testing, and imaging where possible to reduce the chance of person-to-
person transmission of the virus.99 While the FDA has stated that each of 
these guidance documents are only in effect for the duration of the public 
 
90. See U.S. FOOD & DRUG ADMIN., ENFORCEMENT POLICY FOR NON-
INVASIVE REMOTE MONITORING DEVICES USED TO SUPPORT PATIENT MONITORING 
DURING THE CORONAVIRUS DISEASE-2019 (COVID-19) PUBLIC HEALTH 
EMERGENCY (REVISED) (June 5, 2020) [hereinafter REMOTE PATIENT MONITORING 
GUIDANCE]; U.S. FOOD & DRUG ADMIN., ENFORCEMENT POLICY FOR NON-
INVASIVE FETAL AND MATERNAL MONITORING DEVICES USED TO SUPPORT 
PATIENT MONITORING DURING THE CORONAVIRUS DISEASE 2019 (COVID-19) 
PUBLIC HEALTH EMERGENCY (Apr. 23, 2020) [hereinafter FETAL AND MATERNAL 
MONITORING DEVICES GUIDANCE]; U.S. FOOD & DRUG ADMIN., ENFORCEMENT 
POLICY FOR REMOTE OPHTHALMIC ASSESSMENT AND MONITORING DEVICES 
DURING THE CORONAVIRUS DISEASE 2019 (COVID-19) PUBLIC HEALTH 
EMERGENCY (Apr. 6, 2020) [hereinafter REMOTE OPHTHALMIC ASSESSMENT AND 
MONITORING GUIDANCE]. 
91. See CLINICAL TRIALS OF MEDICAL PRODUCTS GUIDANCE, supra note 89. 
92. CLINICAL TRIALS OF MEDICAL PRODUCTS GUIDANCE, supra note 89. 
93. CLINICAL TRIALS OF MEDICAL PRODUCTS GUIDANCE, supra note 89. 
94. See REMOTE PATIENT MONITORING GUIDANCE, supra note 90. 
95. See REMOTE OPHTHALMIC ASSESSMENT AND MONITORING GUIDANCE, 
supra note 90. 
96. See FETAL AND MATERNAL MONITORING DEVICES GUIDANCE, supra note 
90. 
97. See REMOTE DIGITAL PATHOLOGY GUIDANCE, supra note 88. 
98. See CLINICAL TRIALS OF MEDICAL PRODUCTS GUIDANCE, supra note 89. 
99. CLINICAL TRIALS OF MEDICAL PRODUCTS GUIDANCE, supra note 89. 
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health emergency,100 it is not difficult to imagine the convenience to 
patients, providers, participants, and investigators coupled with improved 
and more accurate technologies could outweigh the need to return to 
completely in-person trials and treatments. 
The FDA itself considers its response to COVID-19 innovative, 
specifying five areas and which are reflected in the guidance documents 
discussed above. These include (1) using real-world data to identify 
potential treatments for further study; (2) establishing a 3D printing 
partnership; (3) collaborating with diverse sources across government, 
academia, and industry to promote using real-world data to inform their 
response; (4) creating a treatment acceleration program; and (5) 
accelerating guidance document development to support researchers and 
innovators.101  
The FDA has also been working in collaboration with other 
organizations to accelerate research and improve its COVID response. For 
example, the FDA is a member of the COVID-19 Evidence Accelerator, an 
organization designed to aggregate data and analytics related to the 
epidemic, organized by the Reagan-Udall Foundation for the FDA in 
collaboration with Friends of Cancer Research.102 The Accelerator, which 
includes both a diagnostics and therapeutics branch, is intended to 
complement data and research efforts already underway at the FDA by 
harnessing more real-world data.103 Similarly, in May of 2020, the FDA 
 
100. In fact, the FDA includes the boilerplate statement “This policy is 
intended to remain in effect only for the duration of the public health emergency 
related to COVID-19 declared by HHS, including any renewals made by the HHS 
Secretary in accordance with section 319(a)(2) of the Public Health Service Act (42 
U.S.C. 247d(a)(2)),” on all the guidances classified as relating to COVID-19. 
101. See Innovation to Respond to COVID-19, U.S. FOOD & DRUG ADMIN. 
(July 16, 2020), https://www.fda.gov/emergency-preparedness-and-response/
coronavirus-disease-2019-covid-19/innovation-respond-covid-19 
[https://perma.cc/V288-PEAQ].  
102. See Statement from Amy Abernethy, Principal Deputy Commissioner, 
Office of the Commissioner, Coronavirus (COVID-19) Update: FDA 
Collaborations Promote Rigorous Analyses of Real-World Data to Inform 
Pandemic Response, U.S. FOOD & DRUG ADMIN. (May 19, 2020), 
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-
update-fda-collaborations-promote-rigorous-analyses-real-world-data-inform 
[https://perma.cc/NMV9-J2YB]; COVID-10 Evidence Accelerator, FRIENDS 
CANCER RES., https://www.focr.org/covid19 [https://perma.cc/M89D-2V95] (last 
visited Aug. 24, 2020). 
103. See Coronavirus (COVID-19) Update: FDA Takes Additional Action to 
Harness Real-World Data to Inform COVID-19 Response Efforts, U.S. FOOD & 
DRUG ADMIN. (June 18, 2020), https://www.fda.gov/news-events/press-
announcements/coronavirus-covid-19-update-fda-takes-additional-action-harness-
real-world-data-inform-covid-19 [https://perma.cc/9666-R4C3]; see also Reagan-
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partnered with a data company, Aetion, to examine COVID patient 
medication treatments and related complications.104 Aetion’s software uses 
electronic medical records to generate real-world evidence which the FDA 
can then use to analyze diagnostics, medications, and risk factors for 
COVID-19 in diverse patient populations.105 As part of the collaboration, 
Aetion will review pharmacy claims, electronic medical records, hospitals, 
and labs related to COVID-19 patients.106 
One of the areas where one would expect to see increased 
innovation would be in the development of a COVID-19 vaccine. For 
example, the Evidence Accelerator is incorporating significant real-world 
data in its research. However, the FDA’s vaccine development guidance 
makes no mention of real-world data.107 Rather, it emphasizes that a 
vaccine must be at least 50% more effective than a placebo and that 
showing immune response data alone will not be enough. Arguably, the 
vaccine guidance is novel in that it encourages (but does not require) 
investigators to use a diverse subject pool, including racial and ethnic 
diversity as well as pregnant, elderly, and individuals with other serious 
medical conditions, contrary to historical FDA preference for strict subject 
criteria to avoid confounding variables.108  
IV.  AN EXECUTIVE YEAR IN REVIEW: ACTIVITY WITH POTENTIAL TO 
INFLUENCE FDA OPERATIONS 
Alongside the FDA’s guidance document activity to effectuate 
rapid policy innovation, the White House and Executive Branch officials, 
like former Secretary of HHS Alex Azar, have issued a number of actions 
and orders that implicate the FDA, from an administrative law perspective, 
as they address the regulatory process and guidance documents. Table 4 
details these recent activities. 
 
Udall Found. & Friends of Cancer Rsch., COVID-19 EVIDENCE ACCELERATOR 
(Aug. 24, 2020), https://www.evidenceaccelerator.org/ [https://perma.cc/R3T3-7AF
V] . 
104. See Jacquie Lee, FDA Teams Up With Data Company Aetion to Study 
Virus Progression, FRIENDS CANCER RES. (May 19, 2020), https://www.focr.org/
news/bloomberg-law-fda-teams-data-company-aetion-study-virus-progression-1 
[https://perma.cc/A7TX-U9CN]; see also Statement from Amy Abernethy, supra 
note 102. 
105. See Statement from Amy Abernethy, supra note 102; see generally 
AETION (Aug. 24, 2020), https://www.aetion.com/ [https://perma.cc/AM9S-3T9W].  
106. See Lee, supra note 104. 
107. DEVELOPMENT AND LICENSURE OF VACCINES GUIDANCE, supra note 78. 
108. Jeannie Baumann, FDA Presses Industry to Better Diversify Covid-19 
Testing Pool, BLOOMBERG L. (July 1, 2020), https://bnanews.bna.com/pharma-and-
life-sciences/look-beyond-healthy-volunteers-in-virus-vaccine-tests-fda-says 
[https://perma.cc/U4G3-82NW]. 
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Table 4: Executive Branch Actions 2019–2020 
 
Date Document Source Title/Action 
Oct. 9, 2019 Ex. Order 13891 President Trump Improving the 








Aug. 20, 2020 85 Fed. Reg. 
51396 

















Oct. 21, 2020 Ex. Order 13957 President Trump Creating Schedule 
F in the Excepted 
Service114 
 
109. Exec. Order No. 13,891, 84 Fed. Reg. 55,235 (Oct. 9, 2019). 
110. Exec. Order No. 13,924, 84 Fed. Reg. 31,353 (May 19, 2020). Fox News 
reported that at a Cabinet meeting prior to signing, the President noted “We've 
done far more regulation cutting than any president in history.” See Morgan 
Phillips & Blake Burman, Trump Announces Executive Order to Make Hundreds of 
Deregulations Amid Coronavirus Permanent, FOX NEWS (May 19, 2020), 
https://www.foxnews.com/politics/trump-executive-order-to-identify-regulations-
that-can-be-suspended-for-coronavirus-recovery [https://perma.cc/THY2-UM5S]. 
111. Department of Health and Human Services Good Guidance Practices, 85 
Fed. Reg. 51,396 (Aug. 20, 2020). 
112. HHS Statement on Regulatory Process, U.S. DEP’T. HEALTH & HUM. 
SERVS. (Sept. 20, 2020), https://www.hhs.gov/about/news/2020/09/20/hhs-
statement-on-regulatory-process.html [https://perma.cc/TV5F-W38W].  
113. Cecelia Smith-Schoedenwalder, Report: White House Blocks New FDA 




114. Exec. Order No. 13,957, 85 Fed. Reg. 67,631 (Oct. 21, 2020). 
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Executive Order 13891, Improving the Rule of Law through 
Improved Agency Guidance Documents, specifically addresses the 
procedures for issuing guidance documents and instructs agencies to 
perform a number of tasks with respect to their own guidance documents. 
The order emphasizes the nonbinding nature of guidance documents and the 
requirements that public input be taken into account and the documents be 
readily available to the public.115 The order directs that within 120 days 
after the Office of Management and Budget (OMB) issues an implementing 
memo, each agency “shall establish or maintain on its website a single, 
searchable, indexed database” of guidance documents.116 Agencies are 
further directed to review all guidance documents and rescind those “that 
should no longer be in effect.”117 For guidance documents that are 
identified by the Director of OMB, each agency is required to issue a report 
to the Director giving reasons for maintaining those guidance documents; 
the report is also to be given to the President.118 Agencies are also required, 
within 300 days of the OMB implementing memo, to finalize regulations or 
amend existing regulations setting forth procedures and processes for 
issuing guidance documents, including enumerated requirements identified 
in the order.119 Guidance documents deemed “significant”120 require 
additional aspects under the order, including a 30 day period of public 
notice and comment, as well as a public response from the agency as to 
“major concerns raised in comments, except when the agency for good 
cause finds (and incorporates such finding and a brief statement of reasons 
therefor into the guidance document) that notice and public comment 
thereon are impracticable, unnecessary, or contrary to the public 
 
115. Exec. Order No. 13,891, 84 Fed. Reg. 55,235 (Oct. 9, 2020). 
116. Id. at 55,236. 
117. However, the order does allow the agency to reinstate guidance 
documents within 240 days without regular procedures. See id. at 55,236.  
118. Id. at 55,236–37. 
119. Id. at 55,237. 
120. The order provides:  
“Significant guidance document’’ means a guidance document 
that may reasonably be anticipated to: (i) lead to an annual effect 
on the economy of $100 million or more or adversely affect in a 
material way the economy, a sector of the economy, productivity, 
competition, jobs, the environment, public health or safety, or 
State, local, or tribal governments or communities; (ii) create a 
serious inconsistency or otherwise interfere with an action taken 
or planned by another agency; (iii) materially alter the budgetary 
impact of entitlements, grants, user fees, or loan programs or the 
rights and obligations of recipients thereof; or (iv) raise novel 
legal or policy issues arising out of legal mandates, the 
President’s priorities, or the principles of Executive Order 12866. 
Id. at 55,236. 
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interest.”121 Significant guidance documents also require the approval “on a 
non-delegable basis by the agency head or by an agency component head 
appointed by the President, before issuance” and review by the Office of 
Information and Regulatory Affairs (OIRA) prior to issuance.122 
Executive Order 13924, Regulatory Relief to Support Economic 
Recovery, introduces directives to all agencies given the national health 
emergency of the coronavirus.123 The order urges agencies to examine 
whether regulations are inhibiting recovery and use existing legal authority 
to rescind, modify, or implement exemptions to regulations and other 
requirements.124 It also directs agencies to utilize fairness in administrative 
enforcement and adjudications, including the use of enforcement discretion, 
against businesses, and small businesses in particular, in the face of “often-
complex regulations in complicated and swiftly changing 
circumstances.”125 Agencies are instructed to use emergency authorities and 
are encouraged to proceed through non-regulatory action when 
appropriate.126 As part of agency operations, the order expressly directs 
heads of agencies to:  
identify regulatory standards that may inhibit economic 
recovery and shall consider taking appropriate action, 
consistent with applicable law, including by issuing 
proposed rules as necessary, to temporarily or permanently 
rescind, modify, waive, or exempt persons or entities from 
those requirements, and to consider exercising appropriate 
temporary enforcement discretion or appropriate temporary 
extensions of time as provided for in enforceable 
agreements with respect to those requirements, for the 
purpose of promoting job creation and economic growth, 
insofar as doing so is consistent with the law and with the 
policy considerations.127 
The HHS released a proposed rule in conformance with Executive 
Order 13891 on August 20, 2020. Notably, the proposed rule impacts all 
divisions of HHS except the FDA because the FDA has its own good 
guidance documents, statutory provisions, regulations, and policies and 
procedures.128 The rule creates a distinction between guidelines in 
 
121. Id. at 55,237. 
122. Id.  
123. Exec. Order No. 13,924, 85 Fed. Reg. 31,353 (May 19, 2020).  
124. Id. at 31,353–54.  
125. Id.  
126. Id. at 31,354.  
127. Id.  
128. Erin Atkins & Stephanie Trunk, HHS Proposes New Practices for 
Issuance of Guidance Documents, JD SUPRA (Sept. 2, 2020), https://www.jdsupra.
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“guidance documents” and “significant guidance documents.”129 As a 
reflection of the language in the Executive Order, key features of the 
proposed rule include the role of guidance documents to state policies on 
statutory, regulatory, technical, and scientific issues, or to interpret a 
preexisting regulation.130 HHS notes in the proposed rule that guidance 
documents can be issued in a variety of formats, including letters, 
memoranda, circulars, bulletins, advisories, and preambles, and thus the 
content of the document, rather than the format, would determine whether it 
is a guidance document.131 The proposed rule also exempts categories of 
documents from being under the umbrella of guidance documents.132 
Pursuant to this proposed rule, guidance documents will undergo a thirty-
day notice and comment requirement and will need to be fully supported by 
duly enacted statutes and regulations in order to be compliant with the 
Supreme Court’s ruling in Azar v. Allina Health Services (2019).133 The 
proposed rule also introduces a modified disclaimer, which provides that a 
guidance document does not have the force and effect of law and does not 
bind the public, “unless specifically incorporated into a contract.” 
Furthermore, the disclaimer must state: “This document is intended only to 
provide clarity to the public regarding existing requirements under the 
law.”134135 In all, the proposed rule recites the requirements and directives 
set forth in the Executive Order, and, most importantly, does not apply to 
the FDA. 
On September 15, 2020, Secretary Azar issued a memorandum to 
all federal administrative agencies under the auspices of HHS mandating 
that no regulation should issue unless and until it was approved by the 
Secretary and the White House and the Secretary formally signed that 
regulation.136 The Department in its Statement on Regulatory Process 
provides that this involves “simply the ministerial, administrative act of 
attaching a signature to a document” and was not motivated by policy 
 
com/legalnews/hhs-proposes-new-practices-for-issuance-71156/ [https://perma.cc/
MQY6-B5JB]; Department of Health and Human Services Good Guidance 
Practices, 85 Fed. Reg. 51,396 (Aug. 20, 2020).  
129. Department of Health and Human Services Good Guidance Practices, 85 
Fed. Reg. at 51,396 (Aug. 20, 2020). 
130. Id. 
131. Id. 




136. Statement in Regulatory Process, U.S. DEP’T HEALTH & HUM. SERVS. 
(Sept. 15, 2020), https://www.hhs.gov/about/news/2020/09/20/hhs-statement-on-
regulatory-process.html [https://perma.cc/A6UX-FNHD]. 
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considerations.137 Within the statement the HHS includes the following in 
response to allegations that the action was undertaken to restrict the FDA: 
Was the memo targeted at the Food and Drug 
Administration or any particular divisions of HHS? No, 
the memo covers all Operating and Staff Divisions of HHS. 
Large agencies that release a significant amount of rules, 
such as the Food and Drug Administration, already have 
robust processes for sending any rules through 
departmental and White House clearance. Those processes 
will remain unchanged, except that they will now conclude 
with the Secretary’s signing the rule in all cases.138 
Subsequently, in late September through early October, multiple 
news outlets were reporting that the White House was refusing to accept the 
FDA’s guidance document entitled Emergency Use Authorizations for 
Vaccines to Prevent COVID-19, which was presented to the President as 
required by Executive Order.139 On Face the Nation on September 27, 
White House Chief of Staff Mark Meadows openly questioned the FDA’s 
guidance document: “We’re trying to make sure that the guidance we give 
is not a[n] inhibitor to getting things out fast, but it also doesn’t detract 
from it.”140 There was widespread speculation that the move was politically 
motivated because the measures contained within the guidance document 
regarding demonstrating efficacy and tracing adverse events would have the 
effect of making approval of a vaccine prior to the election impossible.  
On October 6, 2020, the FDA issued Emergency Use 
Authorizations for Vaccines to Prevent COVID-19 by publishing the 
guidance document on its website.141 It is unclear what communications 
were had among the White House, the HHS, and the FDA, but the guidance 
document is currently in effect. Ten days later, on October 16, 2020, the 
Government Accountability Office (GAO) announced that it would 




139. See, e.g., Smith-Schoedenwalder, supra note 113. 
140. Sydney Lupkin, FDA Releases Long-Awaited COVID-19 Guidance, NPR 
(Oct. 6, 2020), https://www.npr.org/sections/health-shots/2020/10/06/920942575/f
da-releases-long-awaited-covid-19-vaccine-guidance [https://perma.cc/4J2C-BYV
G]. 
141. Emergency Use Authorization for Vaccines to Prevent COVID-19, U.S. 
FOOD & DRUG ADMIN. (Oct. 2020), https://www.fda.gov/media/142749/download 
[https://perma.cc/2RFG-5KUG].  
142. Letter from Orice Williams Brown, Managing Dir., U.S. Gov’t 
Accountability Office: Cong. Relations, to Elizabeth Warren, Sen., U.S. Senate 
(Oct. 16, 2020), https://www.warren.senate.gov/imo/media/doc/21-0015%20
2021] PANDEMIC POLITICS, PUBLIC HEALTH, AND THE FDA 329 
The investigation is responsive to a letter penned by Senator Elizabeth 
Warren and jointly signed by Gary Peters, Committee on Homeland 
Security & Governmental Affairs and Patty Murray, Committee on Health, 
Education, Labor & Pensions.143 The letter requested the GAO “review 
whether the CDC and FDA’s scientific integrity and communications 
policies have been violated and whether those policies are being 
implemented as intended to assure scientific integrity throughout the 
agency.”144 
On October 21, 2020, President Trump issued the Executive Order, 
Creating Schedule F in the Excepted Service.145 This order creates Schedule 
F within the excepted service of the government made up of “employees in 
confidential, policy-determining, policy-making, or policy-advocating 
positions.” Agency heads are directed to identify employees within such 
roles and relocate them to the new Schedule F classification.146 The order 
notes “[f]aithful execution of the law requires that the President have 
appropriate management oversight regarding this select cadre of 
professionals.”147 Once moved, such employees will essentially be at-will 
employees, without the current personnel protections afforded to other 
federal workers.148 The response to the order has been swift, with some 
lawmakers moving quickly to introduce legislative bills that would reverse 
the order, which has been dubbed an attack on the public service system, 
while others applaud the new order as a justified executive action.149 
Unquestionably, the order will make it easier for the President to say 
 
Warren.pdf [https://perma.cc/SP6R-ZQKQ] [hereinafter GAO Letter]; see also Dan 
Diamond, Government Watchdog Will Probe Trump Officials Interference at CDC, 
FDA, POLITICO (Oct. 19, 2020), https://www.politico.com/news/2020/10/19/
government-watchdog-trump-cdc-fda-430175 [https://perma.cc/W6NB-6M8M].  
143. GAO Letter, supra note 142; see also Letter from Gary C. Peters et al., 
Sens., U.S. Senate, to Christi A. Grimm, Principal Deputy Inspector Gen., U.S. 
Dep’t of Health & Human Servs. (Oct. 1, 2020), https://www.hsgac.senate.gov/imo
/media/doc/201001_Letter_%20PetersMuarryWarrenSchumerHHS%20Political%2
0Interference%20Letter.pdf [https://perma.cc/BJ9Q-SWT9] [hereinafter Senate 
Letter]. 
144. GAO Letter, supra note 142; see also Senate Letter, supra note 143. 




149. Lawmakers Respond to Executive Order on Schedule F in Excepted 
Service, FED MANAGER (Oct. 27, 2020), https://fedmanager.com/news/lawmakers-
respond-to-executive-order-on-schedule-f-in-excepted-service 
[https://perma.cc/2SM3-PXNM]. 
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“You’re Fired” to a historically insulated class of federal employees 
operating at the highest levels of the government.150  
CONCLUSION 
As this pandemic has evolved, it was clear to all of us that 
some FDA processes needed to be adjusted to 
accommodate the urgency of the pandemic and I think the 
entire FDA team has now seen first-hand that we need to 
take a critical look at some of our processes and policies.151 
FDA Commissioner Stephen Hahn, M.D., May 29, 2020 
The administrative tension was palpable during the Trump 
administration. Some view the pandemic-induced changes to the regulatory 
process as a positive development, providing flexibility to agencies through 
deregulation.152 Others question whether the deregulation activity is 
compromising public health and safety, and destabilizing public confidence 
in the FDA. Throughout it all, Commissioner Hahn assured the public that 
“good science and sound data” would guide the FDA’s decisions on 
vaccines and other products to treat, diagnose, and mitigate the impact of 
COVID-19.153 It remains to be seen what the future holds for the pandemic 
and for administrative functioning of the FDA.  
 
150. Natalie Alms, Trump Order Creates Schedule F, to Speed Hiring and 
Firing in Key Positions, FCW (Oct. 21, 2020), https://fcw.com/articles/2020/10/21/
trump-schedule-f-civil-service.aspx [https://perma.cc/8YMK-F5EP].  
151. Michael Mezher, Hahn: FDA Will Make Some Changes Amid COVID-19 
Permanent, RAPS (June 1, 2020), https://www.raps.org/news-and-articles/news-
articles/2020/6/hahn-fda-will-make-some-changes-amid-covid-19-perm 
[https://perma.cc/FTU3-PFEZ] (quoting Commissioner Stephen Hahn). 
152. Phillips & Burman, supra note 110. “The Trump administration has used 
the pandemic to spur a deregulation campaign, notably removing regulations to 
telemedicine and removing barriers to accelerate coronavirus vaccine or cure 
development.” Id. 
153. Kari Oakes, Hahn: COVID-19 Vaccine Decision Will Be “Deliberative,” 
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Appendix: FDA Guidance Documents,  
January 1, 2020 – October 6, 2020  
Title 




















































































































































Vaccines to Prevent 
COVID-19 
•           •   Oct. 6 
FDA Guidance on 
Conduct of Clinical Trials 
of Medical Products 
during COVID-19 Public 
Health Emergency 
(Updated September 21, 
2020) 
•   •  •    • • •   Sept. 21 
Assessing COVID-19-
Related Symptoms in 
Outpatient Adult and 
Adolescent Subjects in 
Clinical Trials of Drugs 
and Biological Products 
for COVID-19 Prevention 
or Treatment 
•          • •   Sept. 14 
Resuming Normal Drug 
and Biologics 
Manufacturing 
Operations During the 
COVID-19 Public Health 
Emergency 
•          • •  • Sept. 10 
Investigational COVID-
19 Convalescent Plasma; 
Guidance for Industry 
(Updated: September 2, 
2020) 
•           •   Sept. 2 
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Revised 
Recommendations for 
Reducing the Risk of 
Human 
Immunodeficiency Virus 
Transmission by Blood 
and Blood Products 
•           •   Aug. 27 
Manufacturing, Supply 
Chain, and Drug and 
Biological Product 
Inspections During 
COVID-19 Public Health 
Emergency Questions and 
Answers 
•          • •   Aug. 19 
Policy for Temporary 
Compounding of Certain 
Alcohol-Based Hand 
Sanitizer Products During 
the Public Health 
Emergency 
•          •    Aug. 7 
Temporary Policy for 
Manufacture of Alcohol 
for Incorporation Into 
Alcohol-Based Hand 
Sanitizer Products During 
the Public Health 
Emergency (COVID-19) 
•          •    Aug. 7 
Temporary Policy for 
Preparation of Certain 
Alcohol-Based Hand 
Sanitizer Products During 
the Public Health 
Emergency (COVID-19) 
•          •    Aug. 7 
Enforcement Policy for 
Viral Transport Media 
During the Coronavirus 
Disease 2019 (COVID-
19) Public Health 
Emergency 
 • •  •     •     July 20 
Effects of the COVID-19 
Public Health Emergency 
on Formal Meetings and 
User Fee Applications for 
Medical Devices - 
Questions and Answers 
• •        •  •   July 22 
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Development and 
Licensure of Vaccines to 
Prevent COVID-19 
•           •   June 30 




Manufacturing of a 
Device Under Section 
506J of the FD&C Act 
During the COVID-19 
Public Health Emergency 
• •        •     June 19 
Statistical Considerations 
for Clinical Trials During 
the COVID-19 Public 
Health Emergency 
Guidance for Industry 
•         • • •  • June 16 




Distribution of Drug 
Samples During the 
COVID-19 Public Health 
Emergency 
•          •    June 8 
Enforcement Policy for 
Non-Invasive Remote 
Monitoring Devices Used 
to Support Patient 
Monitoring During the 
Coronavirus Disease-
2019 (COVID-19) Public 
Health Emergency 
(Revised) 
• •        •     June 5 
Temporary Policy 
Regarding Preventive 
Controls and FSVP Food 
Supplier Verification 
Onsite Audit 
Requirements During the 
COVID-19 Public Health 
Emergency 
•            • • June 4 
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Institutional Review 




Investigational Drugs and 
Biological Products 
During the COVID-19 
Public Health Emergency 
   •  •     • •   June 2 
Reporting a Temporary 
Closure or Significantly 




Assistance During the 
COVID-19 Public Health 
Emergency 
•            •  May 27 
Effects of the COVID-19 
Public Health Emergency 
on Formal Meetings and 
User Fee Applications — 
Questions and Answers 
•          • •   May 26 
Enforcement Policy for 
Face Masks and 











Systems for Face Masks 
and Respirators During 
the Coronavirus Disease 
2019 (COVID-19) Public 
Health Emergency 
• •        •     May 26 
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Temporary Policy During 
the COVID-19 Public 
Health Emergency 
Regarding the Qualified 
Exemption from the 
Standards for the 
Growing, Harvesting, 
Packing, and Holding of 
Produce for Human 
Consumption 
•            •  May 22 
Temporary Policy 
Regarding Certain Food 
Labeling Requirements 
During the COVID-19 
Public Health 
Emergency: Minor 
Formulation Changes and 
Vending Machines 
•            •  May 22 
Supplements for 
Approved Premarket 
Approval (PMA) or 
Humanitarian Device 
Exemption (HDE) 
Submissions During the 
Coronavirus Disease 
2019 (COVID-19) Public 
Health Emergency 
• •        •  •   May 21 
Temporary Policy for 
Compounding of Certain 
Drugs for Hospitalized 
Patients by Outsourcing 
Facilities During the 
COVID-19 Public Health 
Emergency (Revised) 
•          •    May 21 
Temporary Policy for 
Compounding of Certain 
Drugs for Hospitalized 




During the COVID-19 
Public Health Emergency 
(Revised) 
•          •    May 21 
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Temporary Policy 
Regarding Non-Standard 
PPE Practices for Sterile 
Compounding by 
Pharmacy Compounders 
not Registered as 
Outsourcing Facilities 
During the COVID-19 
Public Health Emergency 
•          •    May 14 
Returning Refrigerated 
Transport Vehicles and 
Refrigerated Storage 
Units to Food Uses After 
Using Them to Preserve 
Human Remains During 
the COVID-19 Pandemic 
•            • • May 12 
COVID-19 Public Health 
Emergency: General 
Considerations for Pre-
IND Meeting Requests 
for COVID-19 Related 
Drugs and Biological 
Products 
•   •       • •   May 11 
COVID-19: Developing 
Drugs and Biological 
Products for Treatment or 
Prevention 
•          • •   May 11 
Policy for Diagnostic 
Tests for Coronavirus 
Disease-2019 during the 
Public Health Emergency 
(Revised) 
 • •  •     •     May 11 
Postmarketing Adverse 
Event Reporting for 
Medical Products and 
Dietary Supplements 
During a Pandemic 
•         • • • •  May 8 
CVM GFI #271 
Reporting and Mitigating 
Animal Drug Shortages 
during the COVID-19 
Public Health Emergency 
•             • May 7 
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Exemption and Exclusion 
from Certain 
Requirements of the Drug 
Supply Chain Security 
Act During the COVID-
19 Public Health 
Emergency 
•          • •   Apr. 30 
Enforcement Policy for 
Remote Digital Pathology 
Devices During the 
Coronavirus Disease 
2019 (COVID-19) Public 
Health Emergency 
• • •    •   •     Apr. 24 
Enforcement Policy for 
Imaging Systems During 
the Coronavirus Disease 
2019 (COVID-19) Public 
Health Emergency 
• •        •     Apr. 23 
Enforcement Policy for 
Non-Invasive Fetal and 
Maternal Monitoring 
Devices Used to Support 
Patient Monitoring 
During the Coronavirus 
Disease 2019 (COVID-
19) Public Health 
Emergency 
• •        •     Apr. 23 
Temporary Policy on 
Repackaging or 
Combining Propofol 
Drug Products During the 
COVID-19 Public Health 
Emergency 







Requirements During the 
COVID-19 Public Health 
Emergency 
•            •  Apr. 22 
  
338 BELMONT LAW REVIEW [Vol. 8: 301 
Policy for the Temporary 
Use of Portable 
Cryogenic Containers Not 
in Compliance With 21 
CFR 211.94(e)(1) For 
Oxygen and Nitrogen 
During the COVID-19 
Public Health Emergency 
•          •    Apr. 20 
Enforcement Policy for 
Telethermographic 
Systems During the 
Coronavirus Disease 
2019 (COVID-19) Public 
Health Emergency 
• •        •     Apr. 16 
Enforcement Policy for 
Digital Health Devices 
For Treating Psychiatric 
Disorders During the 
Coronavirus Disease 
2019 (COVID-19) Public 
Health Emergency 






       •   •    Apr. 13 




Bypass Devices During 
the Coronavirus Disease 
2019 (COVID-19) Public 
Health Emergency 
• •        •     Apr. 6 




During the Coronavirus 
Disease 2019 (COVID-
19) Public Health 
Emergency 
• •        •     Apr. 6 
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Temporary Policy 
Regarding Enforcement 
of 21 CFR Part 118 (the 
Egg Safety Rule) During 
the COVID-19 Public 
Health Emergency 
        •    •  Apr. 6 
Enforcement Policy for 
Infusion Pumps and 
Accessories During the 
Coronavirus Disease 
2019 (COVID-19) Public 
Health Emergency 
• •        •     Apr. 5 
Enforcement Policy for 
Clinical Electronic 
Thermometers During the 
Coronavirus Disease 
2019 (COVID-19) Public 
Health Emergency 
• •        •     Apr. 4 
CVM GFI #270 - 
Guidance on the Conduct 
and Review of Studies to 
Support New Animal 
Drug Development 
during the COVID-19 
Public Health Emergency 
•             • Apr. 3 
Temporary Policy 
Regarding Packaging and 
Labeling of Shell Eggs 
Sold by Retail Food 
Establishments During 
the COVID-19 Public 
Health Emergency 
•            •  Apr. 3 
Alternative Procedures 
for Blood and Blood 
Components During the 
COVID-19 Public Health 
Emergency 
•           •   Apr. 2 
Revised 
Recommendations to 
Reduce the Risk of 
Transfusion-Transmitted 
Malaria 
•           •   Apr. 2 
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Temporary Policy 
Regarding Nutrition 
Labeling of Standard 
Menu Items in Chain 
Restaurants and Similar 
Retail Food 
Establishments During 
the COVID-19 Public 
Health Emergency 
•            •  Apr. 1 
Enforcement Policy for 
Gowns, Other Apparel, 




• •        •     Mar. 30 
Enforcement Policy for 
Sterilizers, Disinfectant 
Devices, and Air Purifiers 
During the Coronavirus 
Disease 2019 (COVID-
19) Public Health 
Emergency 
• •        •     Mar. 29 





Section 506C of the 
FD&C Act Guidance for 
Industry 
•          • •   Mar. 27 
Temporary Policy 
Regarding Nutrition 
Labeling of Certain 
Packaged Food During 
the COVID-19 Public 
Health Emergency 
•            •  Mar. 26 
CVM GFI #269 - 
Enforcement Policy 
Regarding Federal VCPR 
Requirements to 
Facilitate Veterinary 
Telemedicine During the 
COVID-19 Outbreak 
•             • Mar. 24 
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Enforcement Policy for 
Ventilators and 
Accessories and Other 
Respiratory Devices 
During the Coronavirus 
Disease 2019 (COVID-
19) Public Health 
Emergency 
• •        •     Mar. 22 
Policy for Certain REMS 
Requirements During the 
COVID-19 Public Health 
Emergency Guidance for 
Industry and Health Care 
Professionals 
•      •    • •   Mar. 22 
 
 
 
 
